Posts Tagged ‘Alzheimer Disease’

Alzheimer’s patient is taking her chances in clinical trial

Friday, August 6th, 2010

A Pasadena woman undergoes surgery with no guarantee of treatment or positive results. She’s scared, but there isn’t much she can do as scientific advances have been slow.

Gloria Lucio had two pencil-sized holes drilled into her skull in April, part of a procedure to possibly combat her Alzheimer’s disease.

The surgeon may have injected an experimental gene therapy drug deep into her brain. Or, after months of tests, consultations and preparation, the Pasadena woman may not have received any treatment at all.

The willingness to endure such a surgery for a clinical trial with no guarantee of treatment seems extraordinary. But Lucio and her husband, Don Jones, acknowledge a biting reality: Even if she did get the drug, it may not work.

The substance that may have been injected — a virus carrying genes intended to produce a chemical called nerve growth factor — looked promising in a preliminary trial, but so have many other now-failed treatments.

Such are the options for someone with Alzheimer’s disease in 2010.

The Alzheimer’s Assn. recently estimated that cases of the neurological disease, which now affects about 5 million Americans, will more than double in the next 40 years — at enormous personal, social and economic costs.

The report was the latest in a drumbeat of dismal news about Alzheimer’s. In March, a Phase 3 clinical trial of the promising drug Dimebon failed to produce positive results — another highly anticipated experiment gone bust. Medications currently in use can only mitigate early symptoms; none have been found to slow the disease.

“There’s a feeling of desperation, not only among people with Alzheimer’s disease or mild cognitive impairment but also with their family caregivers,” said Gail Hunt, president of the National Alliance for Caregiving.

But behind the gloomy headlines, researchers say they know more about the cunning illness than ever before. They’re developing techniques to identify it in its earliest stages, and within the next decade they expect treatments to slow or forestall the disease.

Given the swelling numbers of those afflicted, any advance can’t come too soon.

“I want to get well,” Lucio said on a rainy morning, a few days before her April surgery. “I want my brain to be healthy. But I’m scared. The holes — how big will they be?”

Her son, Valentin, 18, was sitting nearby. He points to the tip of his pinkie finger. “The holes are this big, Mom.”

She nodded, still worried.

Lucio was reluctant to undergo the experimental treatment but, with a clear understanding of the situation, felt she had no choice. The disease had been making steady advances for years, quietly stealing pieces of her identity.

A former nurse-practitioner and political activist, she was afflicted with Alzheimer’s at an earlier age than most patients. Lucio is homebound now and no longer fixes meals or pays bills. Her short-term memory is a sieve, and her husband and son don’t leave her alone for long.

“How old are you?” she is asked.

“Sixty-eight,” she said, somewhat hesitantly.

She is 57.

“How big are the holes?” she asked again.

http://www.dimebonalzheimers.com/

Dimebon Over Counter Treatment

Boonstraonehour

Air Quality’s One Hour

Auto Transport Montreal  and Car Carrier GTA Ontario

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Alzheimer’s disease No end to dementia

Saturday, July 31st, 2010

Ten years ago people talked confidently of stopping Alzheimer’s disease in its tracks. Now, they realise they have no idea how to do that

DRUG companies are notoriously secretive. The clock starts running on a patent when it is filed, so the longer something can be kept under wraps before that happens, the better for the bottom line. You know something is up, then, when a group of these firms announce they are banding together to share the results of abandoned drug trials. And on June 11th several big companies did just that. They publicised the profiles of 4,000 patients from 11 trials so that they could learn from each other’s failures. An act of selflessness, perhaps, but also one of desperation.

Alzheimer’s disease is one of those things that policymakers would rather hide from. It is, perhaps, the classic illness of old age. Physical frailty is expected, and can be coped with. Mental frailty is much scarier for the sufferer and more demanding for those who have to look after him. It is expensive, too. Alzheimer’s is estimated to cost America alone some $170 billion a year. And it is getting commoner as average lifespans increase. The number of people suffering from the disease is expected to triple by 2050. Effective treatments would thus be embraced with enthusiasm by sufferers and society alike. The right Alzheimer’s drug could earn a drugmaker a lot of money. The incentives are there. But the science has still failed to deliver.

At the turn of the century, Alzheimer’s research seemed promising. A flurry of drugs which treated symptoms of the disorder had just hit the market and researchers were setting out confidently on a deeper investigation of its causes. Understanding those, they felt sure, would result in a cure. It still might, but the truth is that the hoped-for understanding has not come. As a consequence, a long list of would-be cures have failed in late-stage clinical trials, at enormous cost to the companies producing them. The latest of these, Dimebon, made by Pfizer, was abandoned as recently as March, after $725m had been spent on research and development.


Beta testing

The problem of what causes Alzheimer’s is profound. The physical manifestations of the disease that Alois Alzheimer noticed in 1906 are sticky plaques of one type of protein, now known as beta-amyloid, and nerve-cell-engulfing tangles of a second type, called tau protein. Since 1991 the smart money has been on the hypothesis that the disease is caused by the plaques, and that the tangles are mere consequence. For the past two decades, therefore, most attention has been given to developing drugs that will remove amyloid plaques from an affected brain. Five drugs that do this are on the market, but they only delay the onset of dementia. Once their effectiveness has run its course, memory loss and cognitive decline progress unimpeded, and sometimes even accelerate.

Partly as a consequence of this, the plaque theory is waning. Most researchers still believe beta-amyloid is the culprit, but the idea that free-floating protein molecules, rather than the proteins in the plaques, are to blame is gaining ground. This idea is supported by a study published in April in the Annals of Neurology, which showed that mice without plaques, but with floating beta-amyloid, were just as weakened by the disease as mice with both. If that is true in people, too, many more drugs now in clinical trials may prove to be ineffective.

Another fundamental problem is that, whatever is causing the damage, treatment is starting too late. By the time someone presents behavioural symptoms, such as forgetfulness, his brain is already in a significant state of disrepair. Even a “cure” is unlikely to restore lost function. A biochemical marker that indicates the progress of the disease would thus help identify those for whom early action would be advisable, and might help to distinguish people with Alzheimer’s from those with the less hostile forms of forgetfulness that tend to come with old age. Such a marker would also benefit the organisers of clinical trials. They would be able to see more easily whether a drug was working.

To this end, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), established by America’s National Institutes of Health (NIH) in 2004, is measuring the levels of certain proteins in the cerebrospinal fluid of people who may have Alzheimer’s or may go on to develop it. Though the project still has a long way to go, it has already helped develop a test to diagnose the early stages of the disease.

ADNI’s anagram DIAN, the Dominantly Inherited Alzheimer Network, based at Washington University in St Louis, is taking another approach to the biomarker question. Its researchers are studying families with a genetic mutation that triggers the early onset of Alzheimer’s. That terrible knowledge means it is possible to predict which members of a family are destined to get the disease, and compare their biochemistry with that of relatives who do not have the mutation.

It is hard pounding, however, and—as the drug companies’ confession suggests—it is the “R” rather than the “D” of research and development that needs to be emphasised at the moment. A bad time, then, to be cutting back on “R”. That tripling of future sufferers is going to be expensive. Yet Alzheimer’s research, on which the NIH spent $643m in 2006, is to receive only $480m in 2011. It has not been singled out for these cuts. They are part of a general belt-tightening at the agency. But in this as in everything, you get what you pay for. And that might, in the future, be an awful lot of witless, wandering elderly.

http://www.dimebonalzheimers.com/

Dimebon Over Counter Treatment

Boonstraonehour

Air Quality’s One Hour

Auto Transport Montreal  and Car Carrier GTA Ontario

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Alzheimer’s researchers see advances, setbacks

Tuesday, June 15th, 2010

MARIN COUNTY, CA (KGO) — Recent developments in Alzheimer’s research are underscoring the hope and frustration involved in trying to conquer the disease. While potential treatments are moving forward, others have taken a step back.

Former teacher Jean Simpson can still rip through a crossword puzzle with the vocabulary she has built over decades, but at the same time, she no longer has enough short-term memory to read a book.

“I can’t remember once I get to page six. It’s like, ‘Whoops. What was that they said back there?’” she says.

She is taking part in a phase three clinical trial, testing a new drug that shows promise for treating Alzheimer’s disease. It is an open-label trial which means all patients will receive the drug Bapineuzumab.

Alzheimer’s researcher Jerome Goldstein says it is “a medication that addresses the plaques, the amaloy plaques in Alzheimer’s disease.”

Dr. Goldstein says a new imaging technique has allowed researchers to document the drug’s effect on the brains of Alzheimer’s patients, where it was recently shown to reduce clumps of plaque associated with the disease. In clinical trials, patients also showed some slowing of their memory loss.

“At the present time, we see some degree of stabilizations of the disorder,” Goldstein says.

But, in a battle where even marginal progress is a victory, he is still cautious about any long-term predictions for Bapinuezumab.

In early March, another highly-publicized drug, developed in part by Bay Area start-up Medivation, failed a late-stage clinical trial. The future of that drug, Dimebon, is now unclear.

“The main point here is that we’re 100 years into knowing the description of Alzheimer’s disease without any effective treatment,” says Dr. Dale Bredesen at the Buck Institute for Age Research in Marin County.

The Buck Institute is one of several labs now working on alternative targets for Alzheimer’s drugs.

“We have a completely different view of this disease and it used to be thought that the plaques were the bad actors and it looks more now like they’re the garbage dumps. Yes, they can smell bad. Yes, they can look bad, but they’re not the most important thing,” Bredesen says.

Buck Institute researchers have focused on a protein that helps guide nerves and their connections in the brain, rather than targeting the plaque. A video provided by the Buck Institute shows mice, genetically-altered with the same mutation found in people with Alzheimer’s can no longer swim to their target in the pool. But, when scientists alter the protein, the mice quickly find their goal.

That research has evolved and scientists have found the addition of a protein called Netrin-1 has a similar effect.

At Goldstein’s San Francisco clinic, Jean Simpson is hoping the current trial of Bapineuzumab will eventually lead to a new therapy to slow the symptoms of a disease that now affects more than five million people in the U.S.

“So, if they find something with one of us, we’ve gained, and that’s why I’m here,” Simpson says. “I just hope that it works and can help others.”

Johnson & Johnson, the parent company of Elan — the group that is testing Bapineuzumab — has announced that they are extending the length of the clinical trial before they release results. Researchers say the company wants a larger pool of patients before they take their data to the FDA.

Mr Furnaces One Hour

Air Quality’s One Hour

Dimebon Online

http://www.dimebonalzheimers.com/

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Healthy Monounsaturated Fats The fact about fats is that we all need them. Fats are capable of helping in nutrient absorption as well as cell maintenance and nerve transmission. When we consume fats...
  • Blood Test to Test for Early Signs of Alzheimers Disease  Has a blood test for diagnosing Alzheimer's disease finally been discovered?Will it be possible to obtain an accurate diagnosis for Alzheimer's instead of the laborious and complicated diagnosis patients receive now?Keep...
  • Andrew Speaker's TB strain may prove treatable Andrew Speaker, the lawyer who boarded international airline flights with what was believed to be "extensively drug resistant tuberculosis" has had his diagnosis downgraded to "multi-drug resistant tuberculosis" by the...
  • Can Alzheimer's Be Reversed? paul blart mall cop dvdrip MIT scientists now claim they have been able to reverse the effects of Alzheimer's in mice drug trials. wall e dvdrip download twilight dvd wanted...
  • Basics of Alzheimer's Disease Alzheimer's disease is a frightening ailment that affects thousands of people every year. While studies are still being done to determine why exactly this disease hits, research is also being...
  • ITALY - Stem Cells. Zebrafish Provides Hope For Costello Syndrome Patients Mental retardation, altered facial characteristics, and heart problems are all problems suffered by children affected by Costello syndrome, a genetic disease that is being studied by researchers in Milan at...
  • Phentermine With the program that I am on, I am currently taking Phentermine HCl 30mg. With this post I wanted to share what my doctors says about this drug... The page...

Biotech Implosion: Medivation, Alzheimer’s Beats Drug (MDVN, PFE)

Friday, June 11th, 2010

Medivation, Inc. (NASDAQ: MDVN) is the next biotech implosion.  The company’s highly awaited Phase III study on its Alzheimer drug called Dimebon did not meet expectations. It failed to meet primary and secondary endpoints. The problem is that this was hitting 52-week highs yesterday.

The company did note that a separate Phase 3 safety study demonstrated Dimebon’s tolerability when used alone or in combination with approved Alzheimer’s Disease medicines.  Just one more problem… if it doesn’t work it doesn’t matter how tolerable it is.  In some cases the placebo group even did better on the sugar pill, which is perhaps the worst endorsement a company can get.

Furnasman Winnipeg

21 Degrees One Hour

Mr Furnaces One Hour

Dimebon Online

http://www.dimebonalzheimers.com/

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Dimebon Trial Additional Information

Saturday, October 24th, 2009

There are two important aspects to this clinical trial.

* First, when you enter this clinical trial you might receive the placebo, rather than the drug.
* Second, this clinical trial has a good feature–once the six month testing period ends– all patients will be eligible to receive Dimebon in an open-label extension trial.

So here is one note to Dawn. Even if you get the placebo during the clinical trial, you will get the Dimebon at the end of the trial period.

http://www.alzheimersreadingroom.com/2009/03/how-do-you-get-dimebon.html

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Some Good Corporate Blogs It has become popular for businesses and companies of all types to express interest in creating a business blog so that they can better communicate with other companies, their customers,...
  • Off for the Day - Health Blogs That I Read Today is Saturday and I am taking the day off. No working out, not blogging. Just chilling, watching college football, and possibly playing some Monopoly. But before I do that...
  • Barron's on P2P Lending Barron's has just published an online article on p2p lending.  You need to be a subscriber to read it here: At Last, a Bank of Your Own Here is a...
  • WWDC 2010 Recap, iPhone 4 WWDC 2010 kicked off today June 7, 2010 with Steve Jobs giving a keynote introducing the new iPhone 4 and iOS 4. More Pictures and Information: web.mac.com My Website: web.mac.com...
  • Jero singing Enko part 2 More from Gordon: Jerome interviewed by Kyung Lah of CNN/TalkAsia. She lives there too. This reporter is so into this interview. She gets it too, in her way. Jero: American...
  • Finovate Startup 2009 Live Twitter I am attending Finovate Startup 2009. It is an action packed 1 day format which I belive will lend itself perfectly to a live twitter. Stay tuned it should be...
  • The Crawling Chaos of EffectiveCleanse Introduction ...which is Jake's Hollywood Workout.  It's actually a male-focussed advert related to the female-oriented websites I mentioned here.  It has the now-usual "as featured on ABC, CNN" etc with...

Bapineuzumab Clinical Trial in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Saturday, August 15th, 2009

Who is eligible for the study ?

Participants in the Alzheimer’s drug trial must be age 50 to 88, have a diagnosis of probable Alzheimer’s disease and mild to moderate symptoms and have caregivers who are willing to be involved in the study.

At this point, the study has been closed to patients carrying the apolipoprotein E4 aliel, one of the most common genetic markers for the disease.

Participants in the trial receive intravenous infusions of the drug bapienuzumab every three months for a period of 18 months. Researchers will give patients screening tests to evaluate their cognitive skills, daily-living skills and behavioral patterns.

About 60 percent of participants will receive the drug, while the other 40 percent will receive a placebo.

FOR MORE INFORMATION

• Call the Borgess Research Institute at 226-4803 or visit the Web site

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark

Additional Reports Analysis Dimebon Dimebolin Worldwide

Saturday, August 15th, 2009

Dimebon bessert Symptome einer Alzheimer-Demenz

Der vormals als Antiallergikum vermarktete Wirkstoff Dimebon kann den klinischen Verlauf von milden bis moderaten Formen Alzheimer-Krankheit erheblich verbessern, so das Ergebnis einer Langzeituntersuchung. Dimebon zeigte einen stetig zunehmenden Nutzen gegenüber Placebo, was mit keiner anderen gegenwärtig zugelassenen Alzheimer-Therapie erreicht wird.

Der Wirkstoff Dimebon war ab 1983 in Russland als orales Antihistaminikum zur Heuschnupfenbehandlung im Handel, nach der Zulassung von antihistaminischen Wirkstoffen der nächsten Generation verschwand er jedoch aus kommerziellen Gründen wieder vom Markt. Jetzt wurde Dimebon im Hinblick auf seine Wirksamkeit bei neurodegenerativen Erkrankungen getestet. Eine Arbeitsgruppe am Alzheimer’s Disease and Memory Disorders Center in Houston untersuchte die Wirksamkeit von Dimebon bei milden bis moderaten Alzheimer-Formen in einer randomisierten, placebo-kontrollierten Doppelblind-Studie mit 183 Probanden. Ihre kognitive Leistungsfähigkeit wurde in regelmäßigen Abständen anhand der Alzheimer-Disease Assessment Scale – cognitive subscale (ADAS-cog-Skala), sowie vier weiteren Demenztests beurteilt. 155 Patienten beendeten die Studie nach sechs Monaten und zeigten durchgehend positive Ergebnisse. In der Verumgruppe verbesserte sich der ADAS-cog-Wert um 2 Punkte, wohingegen er sich in der Placebo-Gruppe um 2 Einheiten verschlechtere. Zum Vergleich: 2007 gab das IQWiG die Wirkung des Cholinesterasehemmer Donepezil, ebenfalls mit einer Verbesserung von 2 bis 3 Punkten auf der ADAS-cog-Skala an. 134 Patienten entschieden sich nach Beendigung des ersten Studienabschnitts, an einer, weitere sechs Monate dauernden, Extensionsphase teilzunehmen. Zunächst hielt die Verbesserung an, erst ab der 39. Woche war eine allmähliche Verschlechterung zu beobachten. Allerdings waren die Ergebnisse auch nach einem Jahr noch immer besser als zu Beginn der Studie. Die Differenz zwischen der Verum und der Placebo-Gruppe im ADAS-cog stieg während des gesamten Studienverlaufs kontinuierlich an. Dies ist laut den Autoren der Studie besonders bemerkenswert, da dies mit keiner anderen gegenwärtig zugelassenen Alzheimer-Therapie erreicht wird.

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • iPhone 4 / Apple iPad 3G - Micro SIM Card Wer mit seinem iPad oder auch dem iPhone 4G mobil ins Internet will, der braucht eine Micro SIM Karte. Aber was ist das eigentlich? Hier die Lösung und ein Paar...
  • Stem Cell Therapeutics Corp. Announces Completion of Enrollment Stem Cell Therapeutics Corp. or the  wishes to announce the acceptance and publication of the paper entitled "The Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Study" by the journal "Stroke",...
  • Insulated Vinyl Siding's Green Performance Documented in New Study Recent studies that have been sponsored on the behalf of NYSERDA, insulated vinyl siding has demonstrated that it contributes to energy consumption savings as well as savings in CO2 emissions...
  • Es ist da, es ist ein iPhone 4 :-) Nach dem gestrigen Tag und dem vielen Ärger mit der Telekom Hotline und den Mitarbeitern im Telekom Shop Düren, habe ich nun endlich ein iPhone 4. Es ist zwar nicht...
  • (3) Test: iPhone 4 Wir testen Apples neues iPhone 4 und zeigen ausführlich, welche Neuheiten das Gerät zu bieten hat und was sie wert sind. Zu den Highlights gehört zweifellos das extrem hoch aufgelöste...
  • Apple iPad - Test von Golem.de Apple iPad - Test von Golem.de Artikel:www.golem.de Video:video.golem.de Facebook: www.facebook.com Twitter: twitter.com Ort: Berlin Zeit: 23.06.2010 / 19:35 Uhr Das magische Tablet, das Apple versprochen hat, ist das iPad nicht....
  • (1) Test: iPhone 4 Wir testen Apples neues iPhone 4 und zeigen ausführlich, welche Neuheiten das Gerät zu bieten hat und was sie wert sind. Zu den Highlights gehört zweifellos das extrem hoch aufgelöste...

New Additional Alzheimer’s Patients Wanted – Medivation Dimebon Clinical Trial Study July 09

Sunday, July 5th, 2009

It appears that there has almost been a midnight hour last minute reprieve for Alzheimer’s patients and their families wishing to participate or at least to obtain Dimebon for patients and loved ones via the clinical trial route”A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer’s Disease”  is recruiting candidates and is underway

“This study is currently recruiting participants.”

This was only announced recently at Clinical Trials.gov and just verified by Pfizer itself

(Pfizer and Medivation had announced an agreement to co-develop and market Dimebon for treatment of Alzheimer’s Disease.
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer’s Disease
This study is currently recruiting participants.
Verified by Pfizer, June 2009
First Received: February 5, 2009   Last Updated: June 25, 2009   History of Changes
Sponsors and Collaborators:     Pfizer
Medivation, Inc.
Information provided by:     Pfizer
ClinicalTrials.gov Identifier:     NCT00838110

triangle New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09 Purpose

This is a multi-center, randomized, double-blind placebo-controlled safety study conducted in 2 study cohorts. In Cohort 1, subjects with Alzheimer’s disease (n=250) will receive Dimebon 20 mg or placebo TID for 26 weeks. In Cohort 2 AD subjects (n=500) will be treated with Dimebon 20 mg or placebo TID for 12 weeks After completion of the randomized portion of the study, subjects in both Cohorts will have the opportunity to enroll in a Dimebon open label extension study.

Condition     Intervention     Phase
Alzheimer’s Disease     Drug: Dimebon
Drug: Placebo     Phase III
Study Type:     Interventional
Study Design:     Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Parallel Assignment, Safety Study
Official Title:     A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer’s Disease

Resource links provided by NLM:
Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer’s Disease

Drug Information available for: Dimebolin
U.S. FDA Resources

Further study details as provided by Pfizer:
Primary Outcome Measures:

* Adverse events [ Time Frame: 3-6 months ] [ Designated as safety issue: Yes ]
* ECG’s [ Time Frame: 3-6 months ] [ Designated as safety issue: Yes ]
* Vital Signs [ Time Frame: 3-6 months ] [ Designated as safety issue: Yes ]
* Clinical Chemistry / Hematology [ Time Frame: 3-6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:     750
Study Start Date:     February 2009
Estimated Study Completion Date:     March 2010
Estimated Primary Completion Date:     March 2010 (Final data collection date for primary outcome measure)

Arms     Assigned Interventions
Dimebon 20 mg TID (Cohort 1): Experimental     Drug: Dimebon
10 mg TID for week 1 followed by 20 mg TID through Week 26
Placebo TID (Cohort 1): Placebo Comparator     Drug: Placebo
10 mg TID for week 1 followed by 20 mg TID through Week 26
Dimebon 20 mg TID (Cohort 2): Experimental     Drug: Dimebon
10 mg TID for week 1 followed by 20 mg TID through Week 12
Placebo TID (Cohort 2): Placebo Comparator     Drug: Placebo
20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12

triangle New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09 Eligibility
Ages Eligible for Study:     50 Years and older
Genders Eligible for Study:     Both
Accepts Healthy Volunteers:     No
Criteria

Inclusion Criteria:

* Diagnosis of Alzheimer’s Disease.
* MMSE 12-26 inclusive.
* If on existing anti-dementia therapy, have been on a stable dose of anti-dementia therapy (cholinesterase inhibitors and/or memantine) for at least 60 days prior to dosing in study.
* If not taking existing anti-dementia therapy, have not received therapy with cholinesterase inhibitors and/or memantine within 60 days prior to dosing in this study.

Exclusion Criteria:

* Have major structural brain disease (e.g., ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions, or a single lesion in a critical region [e.g., thalamus, hippocampus]).
* Have any major medical illness or unstable medical condition within six months of screening that may interfere with the patient’s ability to comply with study procedures and abide by study restrictions.
* Have not been on a stable dose of anti-dementia therapy for at least 60 days prior to dosing or intend to start anti-dementia therapy during the double blind portion of the study.
* Reside in a nursing home or assisted care facility with need for 24-hour care and supervision.

triangle New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09 Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00838110

Contacts
Contact: Pfizer CT.gov Call Center     cb transparent l New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09us New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09arrow New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09space New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 091-800-718-1021cb transparent r New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09

plus New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09 Show 111 Study Locations
Sponsors and Collaborators
Pfizer
Medivation, Inc.

Investigators
Study Director:     Pfizer CT.gov Call Center     Pfizer

triangle New Additional Alzheimers Patients Wanted Medivation Dimebon Clinical Trial Study July 09 More Information
Additional Information:
To obtain contact information for a study center near you, click here. This link exits the ClinicalTrials.gov site

No publications provided
Responsible Party:     Pfizer, Inc. ( Director, Clinical Trial Disclosure Group )
Study ID Numbers:     B1451027
Study First Received:     February 5, 2009
Last Updated:     June 25, 2009
ClinicalTrials.gov Identifier:     NCT00838110 History of Changes
Health Authority:     United States: Food and Drug Administration

Keywords provided by Pfizer:
Alzheimer’s Disease, Dimebon, Safety, Tolerability

Study placed in the following topic categories:
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Alzheimer Disease
Central Nervous System Diseases
Neurodegenerative Diseases     Brain Diseases
Dementia
Cognition Disorders
Delirium

Additional relevant MeSH terms:
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Alzheimer Disease
Central Nervous System Diseases     Neurodegenerative Diseases
Tauopathies
Brain Diseases
Dementia

ClinicalTrials.gov processed this record on June 30, 2009

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Health Insurance: Two Percent Profit Sunday Paper - November 1st, 2009 Now the figures are in.  The evil greedy immoral health insurance industry has the audacity to post an average profit of 2 percent!  And...
  • Tips for Fire Safety If you want to practice good fire safety, then you are going to need to have a plan in place. If your home or workshop should ever happen to catch...
  • Stem Cell Therapeutics Corp. Announces Completion of Enrollment Stem Cell Therapeutics Corp. or the  wishes to announce the acceptance and publication of the paper entitled "The Beta-hCG + Erythropoietin in Acute Stroke (BETAS) Study" by the journal "Stroke",...
  • 5 Tips to Landing a King Salmon If you are up for a challenge, there is nothing like the feeling of being able to land a king salmon. These fish have an incredible amount of fight in...
  • Safety call over stem cell trips Image via Wikipedia A clampdown on unproven and potentially unsafe stem cell research is being called for by an expert group. Bionet, a group of expert Chinese and European doctors,...
  • Heart Attack Victim Healed in Stem Cell Research Study Image via Wikipedia In a stem cell research study at the University of Miami, Barry Brown has had his heart attack healed after receiving therapy using his own Adult Stem...
  • What are your risks of getting Alzheimer's? Your risk of contracting Alzheimer's disease will most likely increase if  both your parents have it.During a recent study researchers found a larger percentage of children whose parents were diagnosed with Alzheimer's,...

Alzheimer's Disease Clinical Trials Materials

Friday, June 5th, 2009

Research continues on the exciting new compounds for the treatment of Alzheimer’s Disease from the Eli Lily Company.  Some additional information and tidbits on the followup and followthroughs in relation to the medications code named “expedition”  and “expedition2″

Earlier trials suggested VR004 could produce results after only … – Eli Lilly and Company (NYSE LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an antiamyloid beta monoclonal antibody being investigated as a potential … The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2000 patients age 55 and over from 16 countries. …

I Love Earth & Human: <AsiaNet>Lilly Advances Second Alzheimer’s … – EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2000 patients age 55 and over from 16 countries. In 2008, Lilly began enrolling patients in two Phase III clinical … Eric Siemers M.D., Medical Director, Alzheimer’s disease research for Eli Lilly and Company. “Biomarker results from a Phase II solanezumab trial give us hope that Lilly is on a path toward a treatment that may slow the rate of …

Nerviano Medical Sciences Receives Approval From the FDA to Enter … – NERVIANO, Italy – The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. …

??????????????(LY2062430(Solanezumab)P3??) – ?? … – Eli Lilly and Company – Lilly Advances Second Alzheimer’s Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials. http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=385443 … Patients who are taking currently available symptomatic treatments for Alzheimer’s disease can continue treatment during their participation in the EXPEDITION trials. EXPEDITION will be conducted in Argentina, Brazil, Canada, Japan, and United States. …

Gordon & Doner, P.A. v. Jeffrey Joros – Joros=s first amended original petition alleged that he retained Gordon to represent him in claims against Eli Lilly arising out of injuries involving the drug Zyprexa. Suit was to be filed in multidistrict litigation pending in the … Moki Mac River Expeditions v. Drugg, 221 S.W.3d 569, 574 (Tex. 2007); BMC Software Belgium, N.V. v. Marchand, 83 S.W.3d 789, 794 (Tex. 2002). In reviewing a trial court=s ruling on a special appearance, we examine all of the evidence in …

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • A Cure for Alzheimer's? Are we finally getting close to a cure for Alzheimer's? There is a lot of hope concerning the highly successful trials of the new drug Rember. The drug attacks the...
  • The Story of 900 Cats and Oxygen Therapy The Story of 900 Cats and Oxygen Therapy by: Shafin de Zane, CHT, MH, MNLP A DOCTOR from Maryland, USA sued KFC for using a cooking oil that contains high...
  • Stem Cell Research Trial for Congestive Heart Failure Image via Wikipedia Look what we have here- another stem cell research trial for heart disease (congestive heart failure) and another heart patient has his life improved. This time, at...
  • Stem Cell Research Trial For Liver Patients Using Adult Stem Cells Image via Wikipedia In a stem cell research trial that isn’t getting enough news, liver patients are now being treated with their own Adult Stem Cells at Hammersmith Hospital in...
  • Treatment of Breast Cancer Following a breast cancer diagnosis, you are going to need to sit down with your doctors so that you can put together a unique treatment plan. It is important that...
  • Causes of a Heavy Menstrual Period From time to time, all of us experience what we perceive to be a heavy menstrual period, or unusually heavy bleeding during the period of our menstruation. Fortunately, what we...
  • Stem cells used to clean up clogged arteries [HTML1] One in every 20 Americans over the age of 50 suffers from something called, peripheral arterial disease or PAD. It can result in clogged arteries in your legs, which...

Alzhimer's Disease its Incidence in Relation to the Development of Diabetes Mellitius

Monday, May 4th, 2009

New Research Links Diabetes with Development of Alzheimer’s

For some time, diabetes has been linked with vascular dimentia, a type of brain deterioration caused by damage to the brain’s blood vessels. Recent Alzheimer’s disease research also indicates a significant connection between type 2 diabetes and later development of Alzheimer’s disease and memory loss.

A survey of over 13,000 Scandinavian twins shows that those who were afflicted with diabetes before the age of 65 had more than double (225%) the chance of Alzheimer’s of their non-diabetic twin. The presence of both diseases in one twin (but neither in the other) indicates that the link between the two may be more significant than even the hereditary factors in both diseases.

ARE YOU LONELY?: Signs of alzheimer’s disease – A person with Alzheimer’s disease may put these and other items in inappropriate places-such as an iron in the freezer, or a wristwatch in the sugar bowl, then not recall how they got there. 8. Changes in mood or behavior …

Low blood sugar in type 2 diabetics may heighten Alzheimer’s … – Type 2 diabetics with severe low blood sugar may have an increased risk of developing Alzheimer’s disease, according to a new study.

Photos of food and their sugar-cube equivalent – Boing Boing – Regular consumption of fruit is associated with reduced risks of cancer, cardiovascular disease, stroke, Alzheimer disease, cataracts, and some of the functional declines associated with aging. Also, the risks/damage of the various …

Health News Updates: Keyword News: [diabetes] – (HealthDay News) — Diabetes occurs when your blood sugar rises too high because your body doesn’t produce enough of the hormone insulin, or the insulin doesn’t work correctly. Science Daily, Thu, 10 Apr 2008 6:07 AM PDT Diabetes In Mid- life Linked To Increased Risk Of Alzheimer’s Disease http://www.sciencedaily.com/releases/2008/04/080409170343.htm. Men who develop diabetes in mid-life appear to significantly increase their risk of developing Alzheimer’s disease, …

Sweet Poison – But deit soda and light foods have aspartane.Aspartane containing products that actually makes you crave carbohydrates.It is far more likely to make you gain weight. Some physicians warn Aspartane can cause. Alzheimers disease … We fund a product called Krida all natural Sweetner no sugar it is very good Has anyone try it or any feed back on it we picked up at Wallmart Manufacturers and Distributors of Stevia Rebaudiana based in Toronto, Canada. Thanks Nick …

National Alzheimer’s Disease Caregivers Network Malaysia: MORE … – It now seems even more insidious, that the damage may start before someone is diagnosed with full-blown diabetes, back when the body is gradually losing its ability to regulate blood sugar. In fact, the lines are blurring between what specialists call “vascular dementia” and scarier classic Alzheimer’s disease. Whatever it’s labeled, there’s reason enough to safeguard your brain by fighting diabetes and heart-related risks. “Right now we can’t do much about the …

Natural Remedies Blog » Blog Archive » Anti Ageing Nutrition – Reduce fat intake * Reduce intoxicant intake * Reduce sugar intake. You can intake several foods and food supplements to promote the regeneration of the cells and ensure a good circulation of the blood. These are certain common food … EGCG is an extract that helps you to achieve an all round health free from any dreadful disease like “cancer, Alzheimers disease, blood pressure and any heart disease. The better the absorption of the ingredients the better is the health. …

Alzheimer’s Disease, metabolic disorders and the role of diet … – Diets high in fruit, vegetables, fibre and unsaturated fats, and low in sugar, salt and saturated fat are known to reduce the risk of a range of chronic conditions, such as diabetes, heart disease and stroke.

Diabetes Linked with Alzheimer’s Disease: Patients Who Develop … – New research shows that type 2 diabetes doubles a person’s risk of developing Alzheimer’s disease later in life, making the prevention of diabetes even more significant. … type of diabetes, responsible for over 80% of North American diabetes cases. The blood sugar disturbance has been linked to dozens of different health problems, from vision deterioration to stroke – and the latest research points to a connection between diabetes and later development of Alzheimer’s. …

#1 Health Advice » Blog Archive » How to deal with Alzheimer’s disease – They also had more than twice the amyloid plaque in their brains (a sign of Alzheimer’s) and gained 17 percent more weight than the others. It’s unclear if the sugar or weight gain was more to blame, but cutting back seems like a good …

Diabetes and Alzheimer’s disease linked to each other – A new study finds that diabetes’ destructive impact on blood vessels supplying the brain may begin long before the disease can be detected, just when the body begins having trouble regulating blood sugar. …

Coconut Oil and Alzheimer’s Disease – Dr. Mary Newport recounted a riveting story about her husband who was stricken with Alzheimer’s disease at the young age of 58. Thankfully for us all, Dr. Newport didn’t simply accept that this diagnosis would lead to an inevitable … The researchers found that MCTs preserved brain function during periods of low blood sugar without generating the risk of high blood sugar. This is an important finding because one current theory is that certain forms of brain dysfunction …

Diabetes Prevention Protects Your Brain

These findings are of particular concern given the rising numbers of diabetes patients and the aging baby boomer generation. The Mayo Clinic reports that the number of diabetics in the United States is expected to double in the next 40 years – a frightening number, given the mental consequences as these adults reach their later years.

The new findings linking Alzheimer’s with type 2 diabetes highlight the importance of education and action on this totally preventable blood sugar disease.

Dimebon Alzheimer?s Disease

Dimebolin Online Pharmacy Internet

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Stem Cell Research: The Quest Resumes Scientific inspiration can come from anywhere — a person, an event, even an experiment gone awry. But perhaps nothing can drive innovation more powerfully than the passion born of tragedy....
  • How to Find Extra Money In Your Budget There are 2 ways to have extra money for the things you want or need – make more money or spend less. The first one? Not so easy. But spending...
  • Bipolar Disorder: A Crippling Disease That You Should Be Aware Of Many people believe that having a perfectly healthy body means that they will be able to live a normal and productive life. However, having a healthy body alone is not...
  • Is Grazing a Good Idea? For many of us, it's just too hard to get through the day without nibbling on something. If you have issues with your blood sugar being too low, or you...
  • Stem Cells Buy Freedom From Insulin for Type 1 Diabetics A particular type of stem cell transplantation using the patient's own cells led to short-term freedom from insulin injections in 20 of 23 patients newly diagnosed with type 1 diabetes...
  • Comparing Golf Ball Types Golf, just like any other physical sport, is a game that requires both accuracy and precision in order for you to excel in it. In order for you to score...
  • MonaVie Does Not Treat Medical Conditions Every MonaVie distributor will agree... MonaVie is just fruit. With that being the case it's worth looking at what the benefits of fruit are. To get to the point, let's...